Predictive Biosciences, Inc.: Series B $21.8M

Posted in I - Series B, Q - 4Q08, R - NORTH EAST, X - Diagnostic, X - Oncology

Predictive Biosciences (Lexington, MA) an early-stage developer of intervention diagnostic assays for oncology management, closed a $21.8M Series B financing. Participants include New Enterprise Associates, Kaiser Permanente Ventures, Flybridge Capital Partners and Highland Capital Partners.

China Diagnostics Medical Corp Ltd.: Series B $16.5M

Posted in I - Series B, Q - 4Q08, R - INTERNATIONAL, X - Diagnostic, X - Reagent

China Diagnostics Medical (International) a diagnostics company specializing on development, manufacturing and distribution of in vitro diagnostic reagents and instruments, closed a $16.5 Series B financing. Participants include China Healthcare Partnership, WI Harper, Siemens Venture Capital and Softbank China Venture Capital.

Neuroptix Corp.: Series B $18.5M

Posted in I - Series B, Q - 4Q08, R - NORTH EAST, X - Alzheimer's, X - Diagnostic

Neuroptix (Acton, MA) developer of a laser eye scan diagnostic for the early detection of Alzheimer’s Disease, closed a $18.5M Series B financing. Participants include Inventages.

Apitope International, Ltd.: Series A $12.8M

Posted in I - Series A, Q - 4Q08, R - INTERNATIONAL, X - Diagnostic, X - Multiple Sclerosis, X - RA, X - Vaccines

Apitope International (United Kingdome) developer of vaccines and diagnostics for autoimmune and allergic disease, closed a $12.8M Series A financing. Participants include Vesalius Biocapital, Vinnof and the University of Hasslet.

Promosome, Inc.: Series B $9.6M

Posted in I - Series B, Q - 4Q08, R - NORTH EAST, X - Diagnostic, X - Reagent

Promosome (NY, NY) an early-stage platform reagents and diagnostics biotechnology company closed a $9.6M Series B financing. Participants NGN.

Biosystems International, SA: Series A $4.6M

Posted in I - Series A, Q - 4Q08, R - INTERNATIONAL, X - Antibody, X - Diagnostic

Biosystems International (France) developer of monoclonal antibody based diagnostics for onclogy, closed a $4.6M financing. Participants included Societe Generale Asset Management.

Quotient Bioscience Group, Ltd.: Series B $53M

Posted in I - Series B, Q - 3Q08, R - INTERNATIONAL, X - Diagnostic, X - Hematology

Quotient Bioscience Group (United Kingdom) a provider of bioscience analytics and safety evaluation services, closed a $53M Series B financing. Participants include TA Associates.

Pathwork Diagnostics, Inc.: Series B $20M

Posted in I - Series B, Q - 3Q08, R - WEST, X - Diagnostic, X - Oncology

Pathwork Diagnostics (Sunnyvale, CA) molecular diagnostics company focused on oncology, closed a $20M Series B financing. Participants include Abingworth, Advent Venture Partners, Novus Ventures, Prospect Venture Partners, Venrock and Versant Ventures.

Adnavance Technologies, Inc.: Series B $3.6M

Posted in I - Series B, Q - 1Q08, R - INTERNATIONAL, X - Diagnostic, X - MRSA

Adnavance (Canada) developer of DNA detection molecular diagnostic tests for MRSA identification closed a $3.7M Series B financing. Participants include GrowthWorks Capital, JovInvestment Management and Business Development Bank of Canada.

Accumetrics, Inc.: Series D $65M

Posted in I - Series D, Q - 1Q08, R - WEST, X - Diagnostic

Accumetrics (San Diego, CA) develops diagnostic tests for measurement of anti-platelet drug response closed a $28.8M Series D financing, Participants include Arnerich Massena & Associates, BBT Fund, Essex Woodland Health Ventures, RiverVest, PTV Sciences, KB Partners and Kaiser Permanente Ventures.

Atlas Genetics, Ltd.: Series A $4.1M

Posted in I - Series A, Q - 1Q08, R - INTERNATIONAL, X - Diagnostic

Atlas Genetics (England) developer of point-of-care molecular diagnostics for bacterial and viral disease closed a $4.1M Series A financing. Participants include South West Ventures Fund and Finance South Wales Growth Fund.

Alverix, Inc.: Series A $7.7M

Posted in I - Series A, Q - 1Q08, R - NORTH EAST, X - Diagnostic

Alverix (Wayne, Pa) developer of point-of-care diagnostics devices closed a $7.7M Series A financing. Participants include New Venture Partners and Safeguard Scientifics.

Sanarus Medical, Inc: Series E $15M

Posted in I - Series E, R - WEST, X - Diagnostic

Sanarus Medical (Pleasanton, CA) provides minimally invasive products for the diagnosis and treatment of breast tumors closed a $15M Series E round. The deal was led by Easton Capital Partners and Mosaix Ventures and were joined by U.S. Venture Partners, Forward Ventures, Alta Partners, Federated Kaufmann Fund, Pequot Ventures, Industry Ventures and Channel Medical Partners.

« Previous Entries

to top of page...